Compare KD & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KD | LEGN |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.9B |
| IPO Year | N/A | 2020 |
| Metric | KD | LEGN |
|---|---|---|
| Price | $24.29 | $19.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | $39.60 | ★ $64.23 |
| AVG Volume (30 Days) | 1.8M | ★ 2.8M |
| Earning Date | 02-04-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $15,008,000,000.00 | $909,045,000.00 |
| Revenue This Year | $6.40 | $68.20 |
| Revenue Next Year | $3.60 | $47.77 |
| P/E Ratio | $14.42 | ★ N/A |
| Revenue Growth | N/A | ★ 74.75 |
| 52 Week Low | $23.28 | $18.99 |
| 52 Week High | $44.20 | $45.30 |
| Indicator | KD | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 33.76 | 33.26 |
| Support Level | $24.24 | $20.21 |
| Resistance Level | $25.27 | $23.88 |
| Average True Range (ATR) | 0.84 | 1.37 |
| MACD | -0.31 | -0.14 |
| Stochastic Oscillator | 1.70 | 0.97 |
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.